Omission of an Author in the Byline

To the Editor I write on behalf of my coauthors to explain our omission of an author in the byline of our article entitled “Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study,” which was published online December 6, 2017, in JAMA Psychiatry.1 Eva Velthorst, PhD, was inadvertently listed as a collaborating member of the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group, but she should have been listed as an author in the byline.

We had set an internal process to identify all authors at each site who made specific contributions to the manuscript and who met JAMA Psychiatry’s criteria for authorship. This process underwent several rounds of internal review, and we asked the principal investigators at each site to ensure that all authors had been correctly identified and attributed during the drafting of the manuscript. Despite this, Dr Velthorst was incorrectly listed as a collaborating group member. Dr Velthorst contributed substantially to the conceptualization and design of the study and to the acquisition of data, and she was the day-to-day coordinator of the study and its implementation during data acquisition. She was also responsible for collecting local incidence data in Amsterdam. Unfortunately, because Dr Velthorst left Amsterdam after the completion of the data-collection phase of the study to take up a new position, we failed to correctly identify her as an author during the later drafting of the manuscript. We have now addressed this systemic failure, and Dr Velthorst has subsequently completed and submitted the JAMA Psychiatry authorship form indicating her contributions as a coauthor, including revision of the manuscript, approval of the final version, and sufficient participation to take public responsibility of the work.

We have requested that the article be corrected to include Dr Velthorst in the byline, and all authors have approved of this correction.2 We confirm that there are no other authorship errors in this article. We apologize to the readers and editors of JAMA Psychiatry.

James B. Kirkbride, PhD


Corresponding Author: James B. Kirkbride, PhD, Psylife Group, Division of Psychiatry, University College London, Sixth Floor, Maple House, 149 Tottenham Court Rd, London W1T 7NF, England (j.kirkbride@ucl.ac.uk).

Published Online: March 14, 2018. doi:10.1001/jamapsychiatry.2018.0081

Conflict of Interest Disclosures: None reported.

CORRECTION

Omission of Author in Byline: In the Original Investigation titled “Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study,” which was published online December 6, 2017, and in the January 2018 print issue of JAMA Psychiatry,1 Eva Velthorst, PhD, was inadvertently listed as a collaborating member of the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group, but she should have been listed as the 22nd author in the byline. Her affiliations are as follows: Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, the Netherlands, and Departments of Psychiatry and Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Her Author Contributions have also been provided, and a letter of explanation is published with this Correction.2 This article has been corrected online.


Error in Introduction: In the Original Investigation titled “Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial,”1 published online October 18, 2017, and in the December print issue of JAMA Psychiatry, there was an error in the first sentence of the third paragraph of the Introduction. The sentence beginning “The opioid agonist naltrexone...” should read “The opioid antagonist naltrexone...” This article was corrected online.